Can engineered immune cells tackle brain lymphoma?

This trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or systemic lymphoma that has spread to the CNS. Participants receive axi-cel along with two chemotherapy drugs (fludarabine and cyclophosphamide) to help the therapy work. The goal is to assess safety and how well the treatment shrinks tumors, while also learning about potential neurological side effects.